To treat chronic lung infections, PanaecinTM will be delivered directly to the lung
by inhalation. This topical delivery strategy enables localization of high drug concentration
to the infected area and minimizes toxicity associated with high systemic dose. Aridis'
inhalation technology comprise of inhalable liquid nebilized formulation and inhalable
dry powder formulation generated by a proprietary spray drying process and formulation
that can generate stable powders with the necessary aerosol properties for effective
lung delivery.
Spray drying is a cost-effective, scalable drying method that can directly produce
stable pharmaceutical powders with properties that are amendable to lung delivery
or further fabrication into other dosage presentations. This processing method is
widely used in the food industry and is increasingly finding’s its way into the biopharmaceutical
industry. Conventional spray drying involves significant heat input and shear stress
that prohibit a broader application with protein therapeutics and vaccines that are
less stable than insulin. Aridis has developed a proprietary 'Sonic' Atomization
Technology that produces droplets at lower shear and significantly smaller size distribution,
effectively increases the surface area-to-volume ratio which facilitates droplet
evaporation during spray drying. This lowers the processing stress and enables manufacture
of stable inhalable therapeutics and vaccines. Furthermore, our formulated and spray
dried powder are resistant to inactivation under harsh conditions such as high temperature
and organic solvent conditions.
